Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 1876 AL 1890

Characterization of Altered Molecular Pathways in the Entorhinal Cortex of Alzheimer's Disease Patients and In Silico Prediction of Potential Repurposable Drugs

Fagone P, Mangano K, Martino G, Quattropani MC, Pennisi M, Bella R, Fisicaro F, Nicoletti F, Petralia MC.

Genes (Basel). 2022 Apr 15;13(4):703. doi: 10.3390/genes13040703.

Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer's Disease

Ilina A, Khavinson V, Linkova N, Petukhov M.

Int J Mol Sci. 2022 Apr 12;23(8):4259. doi: 10.3390/ijms23084259.

Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis

Veroniki AA, Ashoor HM, Rios P, Seitidis G, Stewart L, Clarke M, Tudur-Smith C, Mavridis D, Hemmelgarn BR, Holroyd-Leduc J, Straus SE, Tricco AC.

BMJ Open. 2022 Apr 26;12(4):e053012. doi: 10.1136/bmjopen-2021-053012.

Therapeutic role of curcumin in adult neurogenesis for management of psychiatric and neurological disorders: a scientometric study to an in-depth review

Ma W, Xu D, Zhao L, Yuan M, Cui YL, Li Y.

Crit Rev Food Sci Nutr. 2023;63(28):9379-9391. doi: 10.1080/10408398.2022.2067827. Epub 2022 Apr 28.

Blood pressure, antihypertensive drugs, and incident frailty: The Multidomain Alzheimer Preventive Trial (MAPT)

Rouch L, Rolland Y, Hanon O, Vidal JS, Cestac P, Sallerin B, Andrieu S, Vellas B, Barreto PS; MAPT/DSA Group.

Maturitas. 2022 Aug;162:8-14. doi: 10.1016/j.maturitas.2022.03.001. Epub 2022 Mar 15.

Combination Therapy in Alzheimer's Disease: Is It Time?

Salehipour A, Bagheri M, Sabahi M, Dolatshahi M, Boche D.

J Alzheimers Dis. 2022;87(4):1433-1449. doi: 10.3233/JAD-215680.

Potential role of IP3/Ca(2+) signaling and phosphodiesterases: Relevance to neurodegeneration in Alzheimer's disease and possible therapeutic strategies

Jyoti Dutta B, Singh S, Seksaria S, Das Gupta G, Bodakhe SH, Singh A.

Biochem Pharmacol. 2022 Jul;201:115071. doi: 10.1016/j.bcp.2022.115071. Epub 2022 May 4.

Editorial: Aducanumab Trials EMERGE But Don't ENGAGE

Schneider LS.

J Prev Alzheimers Dis. 2022;9(2):193-196. doi: 10.14283/jpad.2022.37.

Microglia in the Neuroinflammatory Pathogenesis of Alzheimer's Disease and Related Therapeutic Targets

Cai Y, Liu J, Wang B, Sun M, Yang H.

Front Immunol. 2022 Apr 26;13:856376. doi: 10.3389/fimmu.2022.856376. eCollection 2022.

Mechanistic Insights for Drug Repurposing and the Design of Hybrid Drugs for Alzheimer's Disease

Padhi D, Govindaraju T.

J Med Chem. 2022 May 26;65(10):7088-7105. doi: 10.1021/acs.jmedchem.2c00335. Epub 2022 May 13.

The Broad Range of Research in Alzheimer's Disease and Related Dementias

DeKosky ST, Duara R.

Neurotherapeutics. 2022 Jan;19(1):1-7. doi: 10.1007/s13311-022-01245-4. Epub 2022 May 13.

The Role of the Microbiota-Gut-Brain Axis in the Development of Alzheimer's Disease

Wiatrak B, Balon K, Jawień P, Bednarz D, Jęśkowiak I, Szeląg A.

Int J Mol Sci. 2022 Apr 27;23(9):4862. doi: 10.3390/ijms23094862.

A(2A) Adenosine Receptor: A Possible Therapeutic Target for Alzheimer's Disease by Regulating NLRP3 Inflammasome Activity?

Merighi S, Nigro M, Travagli A, Pasquini S, Borea PA, Varani K, Vincenzi F, Gessi S.

Int J Mol Sci. 2022 May 2;23(9):5056. doi: 10.3390/ijms23095056.

Recent trends of bioconjugated nanomedicines through nose-to-brain delivery for neurological disorders

Agnihotri TG, Jadhav GS, Sahu B, Jain A.

Drug Deliv Transl Res. 2022 Dec;12(12):3104-3120. doi: 10.1007/s13346-022-01173-y. Epub 2022 May 15.

Brexpiprazole-Associated Pisa Syndrome (Pleurothotonus) in a Patient With Dementia

Nagai Y, Yamazaki T, Sugita T, Shibata N.

Clin Neuropharmacol. 2022 May-Jun 01;45(3):72-73. doi: 10.1097/WNF.0000000000000500. Epub 2022 Apr 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias